Some discrepancies can be appreciated in the results for the myeloid malignancies group, characterized by high heterogeneity in disease type and severity, ranging from low- to high-risk MDS patients and to acute myeloid leukemia; furthermore, medications associated to TPO-RA may also confound the picture. The gene discussed is TPO; the disease is myeloid neoplasm.